{"ModuleTitle": "Company Description", "CompanyName": "Intercept Pharmaceuticals, Inc.", "Symbol": "ICPT", "Address": "10 HUDSON YARDS, 37TH FLOOR, NEW YORK, New York, 10001, United States of America", "Phone": "646-747-1000", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company focused on the development and\r\ncommercialization of novel therapeutics to treat progressive non-viral liver\r\ndiseases with a high unmet medical need utilizing our proprietary bile acid\r\nchemistry. Our first marketed product, Ocaliva\u00ae (obeticholic acid or \"OCA\"), is\r\na farnesoid X receptor (\"FXR\") agonist approved in the United States, the\r\nEuropean Union and several other jurisdictions for the treatment of primary\r\nbiliary cholangitis (\"PBC\") in combination with ursodeoxycholic acid (\"UDCA\") in\r\nadults with an inadequate response to UDCA or as monotherapy in adults unable to\r\ntolerate UDCA. In addition to commercializing OCA for PBC under the Ocaliva\r\nbrand name, we are currently developing OCA for additional indications,\r\nincluding nonalcoholic steatohepatitis (\"NASH\"). We are also developing several\r\nother product candidates in various stages of clinical and preclinical\r\ndevelopment.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f25%2f0001558370-20-001314.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Christian Weyer", "title": "Executive Vice President-Research & Development"}, {"name": "Jason A. Campagna", "title": "Chief Medical Officer"}, {"name": "Jerome B. Durso", "title": "Chief Operating Officer"}, {"name": "Mark E. Pruzanski", "title": "President, Chief Executive Officer & Director"}, {"name": "Sandipkumar S. Kapadia", "title": "Chief Financial Officer & Treasurer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}